Dave Morgan on In Phase 2, Donanemab Curbs Cognitive Decline in Early Alzheimer’s
COMMENT I believe the key element for all three antibodies that reduce PET amyloid is that they evade being bound up by monomers and can get sufficient antibody onto the plaques. This is true for BAN2401/lecanemab, aducanumab, and now donanemab. Other Aβ monomer ...